Lorus Therapeutics today announced that its wholly owned subsidiary, GeneSense Technologies Inc., has been allowed a patent by the Canadian Patent Office entitled "Antitumor Antisense Sequences Dir
Morphotek announced today the issuance of United States Patent 6,825,038 covering the regulation of mismatch repair (MMR), a powerful process for generating functional diversity in mammalian cells,
Biolase Technology today announced that it has been granted a new U.S. patent protecting key areas related to its laser pulse technology. U.S. Patent No. 6,821,272, granted by the U.S. Patent
Tercica announced today the filing of a suit for patent infringement in the High Court of Justice (Chancery Division Patents Court) in the United Kingdom against Insmed Incorporated of Glen Allen, Vir
Genaissance Pharmaceuticals received a Notice of Allowance from the United States Patent and Trademark Office for a patent claiming methods for identifying correlations between the safety and effi
GenoMed announced today that it has filed a patent application on two genes linked to common cancers. These are the first new disease genes the company has filed on since its multiple patent applic
Genzyme announced today that it has filed a lawsuit in the District Court of Tel Aviv alleging that Transkaryotic Therapies Inc. has infringed Genzyme's Israeli patent No. 100,715, which covers certai
Measuring the quantity of a certain type of immune cell DNA in the blood could help physicians predict whether a bone marrow stem cell transplant will successfully restore a population of infection-fighting cells called T lymphocytes in a child. This r
The Australian APEC Study Centre has released a report showing how proposals for a patent-based regime to regulate access to genetic resources could inhibit efforts to protect biodiversity and undermi
GenoMed has filed a patent application on two additional genes linked to common cancers. These genes are the third and fourth identified as a result of GenoMed's research in 2005 to date. They have
The patent - entitled Detection of Loss of the Wild-Type p53 Gene - and licensed to Schering-Plough Corporation, was directed both to diagnosis of p53 gene mutations and to therapeutic applications of the p53 gene. In today's decision, all claims of the patent that purported to cover therapeutic applications of the p53 gene were finally revoked on the basis of insufficiency of the patent disclosure, affirming an earlier decision by the opposition division of the EPO. This is Introgen's third successful outcome over a period of years in oppositions involving European p53 gene patents controlled by or licensed to Schering-Plough.
Dr. David L. Parker, Introgen's vice president for Intellectual Property said, "This is a very important win for Introgen on the European patent front as this was the last of the three patents we had identified and targeted for revocation several years ago. In light of today's decision, we do not now see any patent impediment to commercialization of Advexin therapy in Europe."
While some diagnostic applications of the p53 gene remain in dispute, the therapeutic claims of this patent can never be reintroduced, according to the EPO proceedings. Diagnostic applications of the p53 gene are not part of Introgen's commercialization plans. Treatments with Introgen's therapies are not dependent on p53 diagnosis.
Introgen has previously reported favorable results of oppositions against this European patent. An opposition is an administrative proceeding conducted by the European patent office for challenging the validity, and requesting patent revocation, of issued European patents.
To date, Introgen controls 29 issued patents and has a large number of pending patents in the United States and in commercially important foreign countries relating to its Advexin therapy. In addition some patents address adenoviral p53 compositions, production, purification and use in the treatment of cancer. Importantly, some of Introgen's patents that are directed to adenoviral processing, purification and formulation are not limited in scope to Ad-p53 and cover generally commercial scale production and formulation of any adenovirus product.
http://www.introgen.com/